AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01570075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HR
Description: SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
Study NCT01570075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
Study NCT02713217 — intervention group
Intervention type: OTHER
Intervention: Usual Care
Description: This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
Study NCT02713217 — intervention group
Intervention type: OTHER
Intervention: Blended Telemedicine-Based Integrated Care
Description: This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication.
Study NCT03009071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doin (conduction exercise)
Description: Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
Study NCT03009071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
Study NCT03009071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
Study NCT02640794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
Study NCT02640794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
Study NCT00824317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: (15 mg daily), medium (25 mg daily) and high (40 mg daily)
Study NCT00824317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00985348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Keppra)
Description: Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose
Study NCT03383588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
Study NCT03383588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
Study NCT03383588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
Study NCT03383588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
Study NCT03383588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
Study NCT03383588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
Study NCT03383588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
Study NCT03383588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 20 ml subcutaneous NACL 0.9% - saline solution is the placebo
Study NCT01068327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT04110392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chaya (Cnidoscolus chayamansa)
Description: Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
Study NCT00864604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabumetone 750 mg tablets, single dose
Description: A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
Study NCT00864604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabumetone 750 mg tablets, single dose
Description: B: Active comparator Subjects received Teva formulated products under fed conditions
Study NCT00168766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a (Avonex) plus methylprednisolone
Description: oral administration given on 3 consecutive days, monthly as described in protocol.
Study NCT00168766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta-1a (Avonex) plus methylprednisolone
Description: oral administration given on 3 consecutive days, monthly as described in protocol.
Study NCT00323362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
Study NCT00323362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400 mg/day orally, given Days 1-5 and 8-12 every 21 days
Study NCT03113201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
Study NCT03113201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations-Liaison
Description: Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
Study NCT01607398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADOAIR250
Description: 250 mcg inhalation, twice daily, from week0 -12.
Study NCT01607398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation, twice daily, from week0 -12.
Study NCT02135276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eravacycline
Description: All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
Study NCT02633462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing , Myo-inositol
Description: scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
Study NCT02633462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol
Description: only provided treatment with Myo-inositol supplementation (1 gm twice a day)
Study NCT02086968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectafer
Description: 2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
Study NCT02086968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325mg (1 tablet) three times a day for 28 days
Study NCT03280628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Sutures
Description: The patient's doctor will close the patient's laceration with absorbable sutures.
Study NCT03280628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steri-Strips
Description: The patient's doctor will close the patient's laceration with Steri-Strips.
Study NCT03280628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: The patient's doctor will close the patient's laceration with Dermabond.
Study NCT04619134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCSR Program
Description: flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
Study NCT04619134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: hot pack,flexibility training,strengthening exercise.
Study NCT03936946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Content 1
Description: \~30 minute daily audio recordings of content 1 for 28 days
Study NCT03936946 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio Content 1
Description: \~30 minute daily audio recordings of content 1 for 28 days
Study NCT03936946 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Audio Content 2
Description: \~30 minute daily audio recordings of content 2 for 28 days
Study NCT02253199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg.
Study NCT00564486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV, every 6 hours for 24 hours (4 doses total)
Study NCT00564486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV, every 4 hours for 24 hours (6 doses total)
Study NCT00564486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV, every 6 hours for 24 hours (4 doses total)
Study NCT00564486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV, every 4 hours for 24 hours (6 doses total)
Study NCT00552812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent therapy of aortic coarctation
Description: Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
Study NCT02454699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX400
Description: MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
Study NCT02454699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
Study NCT03024359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extra virgin olive oil
Description: 2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
Study NCT04361006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency (RF)
Description: Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
Study NCT04361006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (CRYO)
Description: Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
Study NCT01308762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat killed whole cell M. obuense (IMM-101) 0.1 mg
Description: Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg.
Study NCT01308762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat-killed whole cell M.obuense (IMM-101) 0.5 mg
Description: Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
Study NCT01308762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat killed whole cell M.obuense (IMM-101) 1.0 mg
Description: Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
Study NCT00596973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Ileal transposition with sleeve gastrectomy
Study NCT03458910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV training
Description: Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
Study NCT03232775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment: Physical Exam with Visual Pedagogy and Structure
Description: Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
Study NCT03232775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control: Physical Exam without Visual Pedagogy and Structure
Description: Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
Study NCT00962013 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restoration® Modular Revision Hip System
Description: Restoration® Modular Revision System
Study NCT01132170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg
Study NCT01132170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg
Study NCT00359359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
Study NCT00359359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
Study NCT02406937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral intake of Feihe New Formula
Description: Oral intake of Feihe New Formula
Study NCT02406937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral intake of Feihe Stage 1 Formula
Description: Oral intake of Feihe Stage 1 Formula
Study NCT02406937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Breast Feeding
Description: Oral intake of breast milk
Study NCT04125160 — intervention group
Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring over 16 days
Study NCT04125160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glycaemic markers
Description: Measurement of HbA1c, glycated albumin and fructosamine.
Study NCT03480165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib 20 MG/ML
Description: 1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
Study NCT03480165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
Study NCT03480165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
Study NCT02755727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injection
Description: See Arms
Study NCT02755727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgical Release
Description: See arms
Study NCT02959372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Study NCT02959372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lung ultrasound. The attending physician will not know the result
Study NCT03856632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
Study NCT03856632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RFM
Description: The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.